Disease · MONDO_0004953
invasive ductal breast carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. invasive ductal breast carcinoma. Diseases, record MONDO_0004953. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004953
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
ductal adenocarcinoma, ductal breast carcinoma, infiltrating ductal adenocarcinoma, infiltrating ductal breast carcinoma, infiltrating ductal carcinoma, infiltrating ductal carcinoma of breast, infiltrating ductal carcinoma of the breast, invasive breast ductal carcinoma, invasive ductal adenocarcinoma, invasive ductal carcinoma, invasive ductal carcinoma of breast, invasive ductal carcinoma of the breast, invasive ductal carcinoma, NST, invasive ductal carcinoma, No specific type
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TAMOXIFEN | CHEMBL83 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PALBOCICLIB | CHEMBL189963 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAZEMETOSTAT | CHEMBL3414621 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPIRUBICIN | CHEMBL417 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANASTROZOLE | CHEMBL1399 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CYP19A1 | Aromatase | 2 | Cytochrome P450 19A1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| CCND1 | CDK6/cyclin D1 | 1 | CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | Phase 2 | https://conductscience.org/library/genes/595 | Drugs and targets |
| CDK4 | Cyclin-dependent kinase 4/cyclin D1 | 1 | Cyclin-dependent kinase 4/cyclin D1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1019 | Drugs and targets |
| CDK6 | CDK6/cyclin D1 | 1 | CDK6/cyclin D1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1021 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 1 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| EZH2 | Histone-lysine N-methyltransferase EZH2 | 1 | Histone-lysine N-methyltransferase EZH2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2146 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 1 | DNA topoisomerase II alpha inhibitor | Phase 1 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| TYMS | Thymidylate synthase | 1 | Thymidylate synthase inhibitor | Phase 1 | https://conductscience.org/library/genes/7298 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02764541 | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | Phase 2 | 195 | 2023-08-31 | Breast Cancer | LETROZOLE, PALBOCICLIB, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00003857 | Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ | Phase 3 | 636 | Breast Cancer | TAMOXIFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | Phase 1 | 300 | Breast Cancer | CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01016665 | Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy | Not applicable | 71 | Breast Cancer | ANASTROZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT05023655 | Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | Phase 2 | 20 | Solid Tumor, ARID1A Gene Mutation | TAZEMETOSTAT | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Arm C Endocrine With Palbociclib vs Arm D Endocrine Therapy Alone: Number of Participants With RCB Response in Arm C and Arm D During the Treatment Phase | 10 of 128 | 3 of 60 | 188 | NCT02764541 |
Source Trial comparisons
Papers from its trials21
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004953
GET https://conductscience.org/api/diseases/v1/MONDO_0004953/papers?page=2